Characteristics | Patients (n = 18) |
---|---|
Median age (at recurrence time) | 77 years (range 60–86) |
Gleason grade at diagnosis | |
1 2 3 4 5 | 4 (22.2%) 5 (27.8%) 3 (16.7%) 4 (22.2%) 2 (11.1%) |
Prior Prostatectomy | |
Yes No | 9 (50%) 9 (50%) |
EBRT EQD2 dose received | |
≥ 60 < 70 ≥ 70 | 11 (61.1%) 7 (38.9%) |
Time to relapse (years) | |
< 10 > 10 | 6 (33.3%) 12 (66.7%) |
Type of relapse | |
Biochemical alone Macroscopic alone Both | 0 3 (16.7%) 15 (83.3%) |
Relapse site | |
Intraprostatic/Prostate bed Extraprostatic Both | 15 (83.3%) 0 3 (16.7%) |
Spacer positioning | |
Yes No | 2 (11.1%) 16 (88.9%) |
Median PSA value pre-MRgSBRT (ng/ml) | 1.38 (range 0.14–13.8) |
Re-treatment BED (α/β of 1.5) | |
≤ 213.3 Gy > 213.3 Gy | 12 (66.7%) 6 (33.3%) |
Concurrent ADT | |
Yes No | 10 (55.6%) 8 (44.4%) |